zur Navigation zum Inhalt


A welcome statement from the associate Editor-in-Chief

10/2016 It is with great pleasure that I join the editorial team of memo – Magazine of European Medical Oncology – and take over the new position of the associate Editor-in-Chief. memo is a noteworthy journal that I have been reading with great interest for many years and which has without doubt benefitted my clinical practice. [...]

Mehr zum Thema

<< Seite 1 >>

Novel strategies in the management of chronic lymphocytic leukemia (CLL)

10/2016 ASH meeting 2015

This review discusses promising new approaches in the management of chronic lymphocytic leukemia (CLL) that were recently presented at the annual meeting of the American Society of Hematology meeting in [...]

Reversal of direct oral anticoagulants in hemophilia treatment

10/2016 ASH meeting 2015

During the 57th annual meeting of the American Society of Hematology 2015 in Orlando, Florida, various aspects in the field of hemostaseology were presented. The Choosing Wisely® campaign pointed out the importance of the critical use of diagnostic tools to rule out pulmonary embolism and questioned the relevance of thrombophilia testing in women undergoing routine infertility [...]

Focus on multiple myeloma at ASH 2015

10/2016 Multiple myeloma was prominently featured during the American Society of Hematology 2015 meeting. Important presentations were related to standards of first-line therapy of myeloma, disease assessment, and treatment of relapsed disease. [...]

Antiangiogenic therapies in ovarian cancer

10/2016 Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation and progression of ovarian cancer. Several well-designed phase II and III trials studied the efficacy of antiangiogenic agents in advanced ovarian cancer. [...]

Rationale of an economically driven PD1 biomarker development in lung cancer - an academic dilemma

10/2016 Immunotherapies for second line use in lung cancer have proven to add relevant value compared to standard treatment options; indeed, they are deemed a breakthrough in cancer treatment. The “clinical value” of a certain drug is determined by its effects on relevant endpoints, namely overall survival, tolerability, and quality of [...]

ASH 2015—insights and outlooks

10/2016 In this issue you will find reviewed selected presentations from the ASH meeting 2015—hand-picked by expert hematologists. Every year, groundbreaking information is emerging from this meeting. Thus, this issue of MEMO not only offers a privileged glimpse on the meeting itself, but also provides insight into the forefront of hematologic treatment strategies. [...]

Medizin heute

Aktuelle Printausgaben